Contrast enhanced ultrasound in the detection of liver @entity3 : a prospective multi-centre dose testing study using a @entity1584 microbubble contrast agent ( XXXX ).

@entity1 @entity8 @entity1584 @entity5 @entity31546 @entity3
OBJECTIVE: To conduct a dose testing analysis of @entity1584 microbubble ( @entity31546 ) @entity8 ( @entity8 ) to determine the optimal dose for detection of liver @entity3 in @entity1 with extra-hepatic primary @entity5 . METHODS: 157 @entity1 were investigated with conventional US and @entity8 . @entity8 was performed following intravenous administration of @entity1584 microbubbles (using one dose of either 0.008, 0.08, 0.12 or 0.36  L/kg body weight). Three blinded off-site readers recorded the number and locations of metastatic lesions detected by US and @entity8 . Contrast enhanced CT and MRI were used as the "Standard Of Reference" (SOR). Sensitivity, specificity and accuracy of liver @entity3 detection with US versus @entity8 , for each dose group were obtained. Dose group analysis was performed using the Chi-square test. RESULTS: 165 @entity3 were present in 92 @entity1 who each had 1-7 lesions present on the SOR. Sensitivity of US versus @entity8 (for all doses combined) was 38% and 67% (p   =   0.0001). The 0.12 dose group with @entity8 (78%) had significantly higher sensitivity and accuracy (70%) compared to other dose groups (p   <   0.05). CONCLUSION: The diagnostic performance of @entity8 is dose dependent with the 0.12  L/kg @entity31546 dose group showing the greatest sensitivity and accuracy in detection of liver @entity3 .
